BioLamina AB engages in the development, manufacture, marketing, and sale of laminin cell culture products worldwide. The company offers a range of defined human recombinant laminin matrices that help to culture stem cells and tissue-specific cells, allowing to control and further develop cell research. Its products are used in human ES cell culturing, mouse ES cell culturing, beta cell-islets creation, single cell ES cell culturing, and human ES cells clonal culturing applications. BioLamina AB has a strategic collaboration with CEVEC Pharmaceuticals GmbH. The company was founded in 2009 and is based in Sundbyberg, Sweden.